Open Access
Issue
BioMedicine
Volume 8, Number 3, September 2018
Article Number 16
Number of page(s) 6
DOI https://doi.org/10.1051/bmdcn/2018080316
Published online 24 August 2018
  1. Kamel SR, Omar GM, Darwish AF, Asklany HT, Ellabban AS. Asymptomatic pulmonary hypertension in systemic lupus erythematosus.Minia University, Egypt Clin Med Insights Arthritis Musculoskelet Disord. 2011; 4: 77–86. [Google Scholar]
  2. Kim KJ, Baek IW, Park YJ, Yoon CH, Kim WU, Cho CS. Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy. Autoimmunity review. 2013; 12: 410–5. [CrossRef] [Google Scholar]
  3. Hao YJ, Jiang X, Zhou W, Wang Y, Gao L, Wang Y, et al. Connective tissue disease- 416 associated pulmonary arterial hypertension in Chinese patients. Eur Respir J. 2014; 417 44(4): 963–72. [CrossRef] [PubMed] [Google Scholar]
  4. Lian F, Dongying Chen D. Clinical features and independent predictors of pulmonary arterial hypertension in systemic lupus erythematosus. Rheumatol Int. 2012; 32: 1727–31. [CrossRef] [PubMed] [Google Scholar]
  5. Dhala A. Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: Current Status and Future Direction. Clinical and Developmental Immunology. 2012; 1–13. [CrossRef] [Google Scholar]
  6. Reátegui-Sokolova C, Ugarte-Gil M. Serum uric acid levels contribute to new renal damage in systemic lupus erythematosus patients. Clin Rheumatol. 2016. 1–5. [Google Scholar]
  7. Sheikh M, Movassaghi Sh. Hyperuricemia in systemic lupus erythematosus: is it associated with the neuropsychiatric manifestations of the disease? revbrasreumatol. 2016; 56(6): 471–7. [Google Scholar]
  8. Ki Min H, Ho Lee J, Min Jung S R, Lee J. Pulmonary hypertension in systemic lupus erythematosus: an independent predictor of patient survival. Korean J Intern Med. 2015; 30: 232–41. [CrossRef] [PubMed] [Google Scholar]
  9. Zharikov S, wenson E, Lanaspa M, Block E. Could Uric Acid be a Modifiable Risk Factor in Subjects with Pulmonary Hypertension? Med Hypotheses. 2010; 74(6): 1069–74. [CrossRef] [Google Scholar]
  10. Kim K, Beak I, Park Y, Yoon C, Kim W, Cho C. High levels of uric acid insystemic lupus erythematosus is associated with pulmonary hypertension. Int J Rheum Dis. 2015; 18(5): 524–32. [CrossRef] [PubMed] [Google Scholar]
  11. Bendayan D, Shitrit D, Ygla M, Huerta M, Fink G, Kramer MR. Hyperuricemia as a prognostic factor in pulmonary arterial hypertension. Respir Med. 2003; 97: 130–3. [CrossRef] [PubMed] [Google Scholar]
  12. Lipsky P. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nature Immunology. 2001; 2: 764–6. [CrossRef] [PubMed] [Google Scholar]
  13. Pistiner M, WallaceMD D. Lupus erhythmatosus in the 1980s: A survey of 570 patients. Semin Arthritis Rheum. 1990. 21(1). [Google Scholar]
  14. Heuer S, Catalina M, Robl R, Geraci N, Lipsky P, Grammer A. Common Patterns of Gene Expression in Tissues of Patients with Systemic Lupus Erythematosus Imply Similar Pathways of Molecular Pathogenesis. J Immunol. 2017, 198 (1 Supplement) 224.17. [Google Scholar]
  15. Winchester, R. J. In Arthritis and Allied Conditions 13th edn. (ed. Koopman, W. J.) 1361–1391 (Lippincott Williams and Wilkins, Baltimore, MD, 1997). [Google Scholar]
  16. Dubois EL. Systemic lupus erythematosus: Recent advances in its diagnosis and treatment. Ann Intern Med. 1956, 45:163–84. [CrossRef] [PubMed] [Google Scholar]
  17. Dubois EL, Tuffanelli DL: Clinical manifestations of systemic lupus erythematosus. JAMA. 1964, 190: 104–11. [CrossRef] [PubMed] [Google Scholar]
  18. Dubois EL, Wierzchowiecki M, Cox MB, et al. Duration and death in systemic lupus erythematosus: An analysis of 249 cases. JAMA. 1974, 227: 1399–402. [CrossRef] [PubMed] [Google Scholar]
  19. Wallace DJ, Podell T, Weiner J, et al. Systemic lupus erythematosus: Survival patterns. Experience with 609 patients. JAMA. 1981, 245: 934–8. [CrossRef] [PubMed] [Google Scholar]
  20. Wallace DJ, Dubois EL (eds). Lupus Erythematosus (ed 3). Philadelphia, PA, Lea & Febiger, 1987. [Google Scholar]
  21. Christie M, Bartels MD. MS. Chief Editor: Herbert S Diamond. Systemic Lupus Erythematosus (SLE). Med Scap. 2017; 1–8. [Google Scholar]
  22. Patrick Blanco, A. Karolina Palucka, Michelle Gill, Virginia Pascual, Jacques Banchereau. Induction of Dendritic Cell Differentiation by IFN-a in Systemic Lupus Erythematosus. Science. 2001; 294: 55461540–1543. [Google Scholar]
  23. Bennett L, A., Palucka A, Arce E, Cantrell V. Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood. JEM Home. 2003; 197 (6): 711. [Google Scholar]
  24. Paul E., Love, MD, PhD; Samuel A. Santoro. Antiphospholipid Antibodies: Anticardiolipin and the Lupus Anticoagulant in Systemic Lupus Erythematosus (SLE) and in Non-SLE Disorders: Prevalence and Clinical Significance. Ann Intern Med. 1990; 112(9): 682–98. [CrossRef] [PubMed] [Google Scholar]
  25. Banchereau J, Virginia Pascual. Type I Interferon in Systemic Lupus Erythematosus and Other Autoimmune Diseases. Immunity. 2006; 25(3): 383–392. [CrossRef] [PubMed] [Google Scholar]
  26. Wu J, Wilson J, He J, Xiang L. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest. 1996. 1: 1. [Google Scholar]
  27. Fisher, G.H., F.J. Rosenberg, S.E. Straus, J.K. Dale, L.A. Middleton, A.Y. Lin, W. Strober, M.J. Lenardo, J.M. Puck. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 1995;81: 935–46. [CrossRef] [PubMed] [Google Scholar]
  28. Rieux-Laucat, F., F. Le Deist, C. Hivroz, I.A. Roberts, K.M. Debatin, A. Fischer, J.P. de Villartay. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science(Wash. DC). 1995; 268: 1347–9. [CrossRef] [PubMed] [Google Scholar]
  29. Luo RQ, Lei YX, Zhang X, Liang F. Clinical analysis of patients with systemic lupus erythematosus and concomitant pulmonary hypertension. Nan Fang Yi Ke Da Xue Xue Bao. 2008; 28(10): 1860–3. [PubMed] [Google Scholar]
  30. Kim KJ, Baek IW, Park YJ, Yoon CH, Kim WU, Cho CS. Levels of uric acid may predict the future development of pulmonary hypertension in systemic lupus erythematosus: a seven-year follow-up study. Lupus. 2016; 25(1): 61–6. [CrossRef] [PubMed] [Google Scholar]
  31. Castillo-Martínez D, Marroquín-Fabián E, Lozada-Navarro AC, Mora-Ramírez M, Juárez M, Sánchez-Muñoz F, et al. Levels of uric acid may predict the future development of pulmonary hypertension in systemic lupus erythematosus: a seven-year follow-up study. Rheumatol Int. 2011; 31(2): 263–7. [CrossRef] [PubMed] [Google Scholar]
  32. Zhang Ch-Y, Ma L, Wang L. Relationship between serum uric acid levels and ventricular function in patients with idiopathic pulmonary hypertension. Exp Clin Cardiol. 2013; 18(1): e37–e39. [Google Scholar]
  33. Xia YK, Tu SH, Hu YH, Wang Y, Chen Z, Day HT, Ross K. Pulmonary hypertension in systemic lupus erythematosus: a systematic review and analysis of 642 cases in Chinese population. Rheumatol Int. 2013; 33(5): 1211–7. [CrossRef] [PubMed] [Google Scholar]
  34. Min HK, Lee JH, Jung SM, Lee J, Kang KY, Kwok SK, et al. Pulmonary hypertension in systemic lupus erythematosus: an independent predictor of patient survival Lupus. Corean j Intern Med. 2015 Mrc; 30(2): 232–41. [Google Scholar]
  35. Murin S P., Wiedemann H, Richard A. Matthay R. Pulmonary manifestation of systematic lupus erythematosus. Clinics in Chest Medicine. 1998; 19(4): 641–65. [CrossRef] [PubMed] [Google Scholar]
  36. Maiuolo J. Regulation of uric acid metabolism and excretion. Int J Cardiol Heart. 2016; 213(5): 8–14. [CrossRef] [Google Scholar]
  37. Chaudhary K, Malhotra K, Sowers J, Aroor A. Uric acid - key ingredient in the recipe for cardiorenal metabolic syndrome. Cardiorenal Med. 2013; 208–20. [CrossRef] [PubMed] [Google Scholar]
  38. Pasalic D, Marinkovic, N, Feher-Turkovic L. Uric acid as one of the important factors in multifactorial disorders - facts and controversies. Biochem Med (Zagreb). 2012; 22(1): 63–75. [CrossRef] [PubMed] [Google Scholar]
  39. Murin S, PWiedemann H, Richard A. Matthay R. Pulmonary manifestation of systematic lupus erythematosus. Clin Chest Med. 1998; 19(4): 641–65. [CrossRef] [PubMed] [Google Scholar]
  40. Khetarpal R, Goraya JS, Singh S, Singh M, Kumar L. Pulmonary hypertension as presenting feature of childhood SLE: association with lupus anticoagulant. Scand J Rheumatol. 1997; 26(4): 325–6. [CrossRef] [PubMed] [Google Scholar]
  41. Kamel R. Asymptomatic Pulmonary Hypertension in Systemic Lupus Erythematosus Shereen Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders. 2011: 4. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.